Metabolic perturbations that decrease or limit blood glucose-such as fasting or adhering to a ketogenic diet-reduce epileptic seizures significantly. To date, the critical links between altered metabolism and decreased neuronal activity remain unknown. More
generally, metabolic changes accompany numerous CNS disorders, and the purines ATP and its core molecule adenosine are poised to translate cell energy into altered neuronal activity. Here we show that nonpathological changes in metabolism induce a purinergic autoregulation of hippocampal CA3 pyramidal neuron excitability. During conditions of sufficient intracellular ATP, reducing extracellular glucose induces pannexin-1 hemichannel-mediated ATP release directly from CA3 neurons. This extracellular ATP is dephosphorylated to adenosine, activates neuronal adenosine A 1 receptors, and, unexpectedly, hyperpolarizes neuronal membrane potential via ATPsensitive K + channels. Together, these data delineate an autocrine regulation of neuronal excitability via ATP and adenosine in a seizure-prone subregion of the hippocampus and offer new mechanistic insight into the relationship between decreased glucose and increased seizure threshold. By establishing neuronal ATP release via pannexin hemichannels, and hippocampal adenosine A 1 receptors coupled to ATP-sensitive K + channels, we reveal detailed information regarding the relationship between metabolism and neuronal activity and new strategies for adenosine-based therapies in the CNS.
COMMENTARY
A lthough severe hypoglycemia is a well-known precipitant of seizures in both human and animal models, there is mounting clinical and experimental evidence that a more modest reduction in blood glucose can be highly effective in controlling intractable epilepsy (1, 2) . The best clinical examples linking glucose restriction with seizure control come from decades of clinical experience with the ketogenic diet (1) and more recently, from studies utilizing a low glycemic index treatment in pediatric patients with medically refractory epilepsy (2) . Intriguingly, calorie restriction, which shares the common feature of limited glucose with both low glycemic index treatment and the ketogenic diet, has been shown to retard aging in organisms from yeast to nonhuman primates (3) and exerts neuroprotective activity (4) . While the anticonvulsant (and neuroprotective) mechanisms underlying glucose restriction remain unclear, prior animal studies have shown that pharmacological attenuation of glycolytic flux, with either 2-deoxy-D-glucose (2-DG, an inhibitor of phosphoglucose isomerase) or fructose-1,6-bisphosphate (which diverts substrates to the hexose monophosphate shunt [also known as the pentose phosphate shunt or PPP]), significantly retards seizure progression in the rat kindling model of temporal lobe epilepsy (5) and blocks acute seizure provocation in a number of established animal models (6), respectively. As a caveat, it should be noted that 2-DG has recently been found to exert proconvulsant effects in other acute seizure models, specifically the mouse electroshock, intravenous pentylenetetrazol, and intravenous kainic acid tests (7) . Thus, it would appear that 2-DG, per se, may yield opposing effects depending on the net effects of glucose uptake, glycolytic activity, and shunting to the PPP.
So how might inhibition of glycolysis prevent seizure activity? It has long been speculated that glucose restriction could limit a neuron's ability to reach (and maintain) the high levels of synaptic activity necessary for sustaining seizure activity. In other words, a deficiency of energy reserves would be akin to a fire extinguishing itself due to lack of oxygen. However, it is unlikely that such a change in bioenergetics could account for the seizure protection conferred by reduced glucose. There is little evidence that the triggering or termination of seizures under ordinary conditions is a consequence of energy failure, although it is well recognized that hypometabolism exists interictally in epileptic foci (8) and that MR spectroscopic studies of patients with epilepsy show significant decreases in bioenergetic substrates in epileptogenic zones (9) .
A more plausible explanation may lie in the intricacies of purinergic signaling within the CNS (10, 11) . ATP and adenosine are critical mediators that play fundamental roles in cellular energetics and intercellular communication, and as such, are prime candidates linking metabolism with neuronal activity.
Moreover, because of their important role in modulating cellular homeostasis, especially in the face of stress or injury, these purines may provide neuroprotective actions, possibly during the course of epileptogenesis (12) .
Against this burgeoning scientific backdrop, Kawamura and colleagues evaluated the electrophysiologic effects of reduced glucose-importantly, under conditions of adequate or enhanced intracellular ATP levels that are similar to the ketogenic diet (13)-in CA3 hippocampal pyramidal neurons, using whole-cell recording techniques. They chose to examine pyramidal neurons in CA3, since this is a highly seizure prone area of the brain. Upon reducing glucose to 3 mM, the investigators observed a significant but reversible hyperpolarization (an outward current) in CA3 pyramidal neurons and a concomitant decrease in input resistance-effects that were critically and bidirectionally determined by the concentration of intracellular ATP. Further, they showed the hyperpolarizing current induced by reduced glucose was abrogated in adenosine receptor-1 (A 1 R) knockout hippocampal slices, thereby invoking adenosine receptor activation as a critical step in explaining their initial electrophysiological observations. Postsynaptic activation of A 1 Rs traditionally has been associated with G-protein-coupled inwardly rectifying K + channels in CA1 pyramidal neurons, so the investigators reasoned that CA3 pyramidal neurons might exhibit the same phenomenon. Certainly, based on the reversal potential and shape of the I-V (current-voltage) relationship of the low glucose-induced outward current, this seemed plausible. However, they were surprised to find indirect evidence that the reduced extracellular glucose-induced outward current might be mediated by the opening of postsynaptic ATP-sensitive potassium (K ATP ) channels linked to the initial activation of A 1 Rs, as demonstrated by blockade of the outward current by 500 μM tolbutamide. While the authors made this intriguing connection to K ATP channels, they did not reconcile the fact that intracellular ATP levels were maintained at normal levels, and it is well known that K ATP channels are activated when ATP levels are low. Thus, the precise manner in which low extracellular glucose and A 1 R activation could be coupled to K ATP channels remains unclear.
To extend these findings, Kawamura and colleagues asked how extracellular ATP might be released and then rapidly degraded by ectonucleotidases into adenosine under their experimental conditions of low glucose. Although several mechanisms for adenosine release have been described in the literature (10), one target of major interest is the gap junction pannexin family of large-pore channels (or hemichannels), which can conduct molecules smaller than approximately 1 kD and have been implicated as a mechanism of direct ATP release from neurons (14) . Thus, to determine whether CA3 pyramidal neurons were responsible for directly releasing ATP, Kawamura et al. applied both selective and nonselective gap junction hemichannel antagonists and found that both presynaptic and postsynaptic A 1 R activation occurred subsequent to ATP released by hemichannels under conditions of reduced extracellular glucose. They showed that the specific pannexin hemichannel inhibitor 10 panx significantly blocked or prevented the outward current induced by low extracellular glucose. Together, their results revealed a novel mechanism of metabolic autocrine regulation of CA3 neurons involving close co-operativity among pannexin hemichannels, adenosine receptors, and possibly K ATP channels.
Overall, this is a highly novel study, as it strongly implicates pannexin-1 hemichannels as a mechanistic target of reduced glucose. How exactly pannexin-1 channels become activated in response to restricted glycolytic flux remains uncertain and is an important question to pursue in the future. The report by Kawamura and colleagues is also intriguing because it is the first demonstration that postsynaptic A 1 receptors could potentially couple to K ATP channels in hippocampal CA3 pyramidal neurons, again providing fertile grounds for further investigation.
Given the similarities between the experimental conditions employed by Kawamura et al. and the metabolic changes observed during ketogenic diet treatment in patients with epilepsy-specifically, an increase in bioenergetic reserves (14) and reduced blood glucose (1)-it is tempting to invoke this intriguing metabolic interplay as the mechanistic basis of the ketogenic diet. Specifically, with respect to implicating K ATP channels, it should be further noted that their data support the observations of Ma et al. (15) , who showed that ketones bodies, elaborated by the ketogenic diet, can attenuate the intrinsic firing of GABAergic pars reticulata neurons in the substantia nigra (a putative subcortical seizure gate), through the opening of K ATP channels. However, Kawamura and colleagues bring greater mechanistic relevance to seizure genesis than do Ma et al., as the findings were made in CA3, which, as mentioned, is more widely viewed as a seizure-susceptible area of the brain.
In assessing the significance of this study, there are a couple of additional important caveats. First, the experimental findings of Kawamura and colleagues were observed in normal (not epileptic) and adult (not pediatric) rat brain. Whether or not their findings translate to the pathological or clinical condition remains unclear. Second, the authors used a nonpathological and physiologically relevant condition (i.e., ATP was maintained at adequate or enhanced bioenergetic levels) to show that reducing glucose has an inhibitory effect on CA3 pyramidal neurons. While adequate ATP may be observed during ketogenic diet treatment, the finding is in stark contrast to human epilepsy data derived from detailed magnetic resonance spectroscopic studies demonstrating deficits in bioenergetic substrates in the epileptic hippocampus (10) . Finally, how do the experimental data provided by Kawamura et al.
relate to the phenomenon of hypoglycemia-induced seizures? Perhaps the severity of hypoglycemia, with diminished output from glycogenolysis, might lead to severely reduced intracellular ATP levels, such that even activation of K ATP channels under these conditions could not overcome the destabilization of the cellular membrane potential that results from the impairment of critical pumps, such as the Na + ,K + -ATPase. Notwithstanding the usual concerns raised when detailed investigations of this type are conducted on normal nonepileptic neurons, this compelling study by Kawamura and colleagues provides yet another molecular target that may play a pivotal role in reducing seizures under conditions of reduced glycolytic flux and helps fill an important gap in understanding how metabolic changes or adaptations yield profound effects on neuronal excitability and integrity.
by Jong M. Rho, MD T he steroid hormone progesterone has long been known to have anticonvulsant properties. Seizure protection is not conferred by progesterone itself, but rather by the progesterone metabolite allopregnanolone, a member of a class of endogenous steroids commonly referred to as neurosteroids (1 allopregnanolone is a powerful anticonvulsant. Although neurosteroids act on all GABA A -receptor isoforms, including those localized at synapses, they produce especially large effects on nonsynaptic δ-subunit containing GABA A -receptor isoforms. Recent evidence indicates that neurosteroids are present predominantly, if not exclusively, in principal (excitatory) neurons in many brain regions that are relevant to focal epilepsies, including the hippocampus and neocortex (2) . All of the enzymes required for neurosteroid synthesis are expressed in the brain. Although it had previously been speculated that brain neurosteroidogenesis occurs in astrocytes, new immunohistochemical evidence indicates that GABA A -receptor modulatory neurosteroids may not be present in glia or in nonpyramidal neurons (i.e., interneurons). The highly restricted distribution of neurosteroids to excitatory neurons suggests that they are mainly derived from local synthesis and not from the circulation, although it is clear that peripheral neurosteroids do easily cross the blood-brain barrier.
The factors that regulate local neurosteroid synthesis are obscure. However, since GABA A receptors are also localized to principal neurons, neurosteroids may serve an autocrine role to influence the functional activity of the very neurons in which they are synthesized. Recently, evidence has accumulated that neurosteroids influence GABA A receptors by binding to discrete sites on the receptor complex located within the transmembrane domains of α and β GABA A -receptor subunits (3) and that they access these sites by lateral membrane diffusion (4) . Neurosteroids are viewed as high-potency modulators of GABA A receptors, since they are effective at concentrations in the range of 1 μM and below in aqueous solution. However, neurosteroid binding to the GABA A receptor is of low affinity (K d , ∼1 mM), and the high effective potency of neurosteroids results from partitioning of the lipophilic steroids within the plasma membrane, such that the concentrations presented to the receptor are orders of magnitude greater.
Given the emerging understanding of the role of neurosteroids as autocrine modulators of neuronal excitability, the question arises as to whether endogenous neurosteroids regulate seizure susceptibility. Lawrence et al. provide important new evidence that the availability of neurosteroids does indeed critically influence the propensity for seizures. These investigators used epileptic female rats that had experienced a prolonged bout of status epilepticus induced by lithiumpilocarpine treatment. Spontaneous seizure activity was monitored by continuous video-EEG recording. The epileptic animals exhibited about six seizures per day, each lasting approximately a minute. However, when neurosteroids were withdrawn, using the neurosteroid synthesis inhibitor finasteride, an enormous (more than ten-fold) increase in seizure frequency was observed. In contrast, finasteride-a selective inhibitor of 5α-reductase, the first and rate-limiting enzymatic step in the synthesis of neurosteroids from their steroid hormone precursors (e.g., progesterone)-did not induce seizures in normal animals.
Similarly, there is no evidence that finasteride causes seizures in humans who do not have epilepsy. Finasteride is used clinically for the treatment of benign prostatic hypertrophy and male pattern hair loss. Seizures have not been reported as an adverse event of finasteride treatment, and given the long experience with the drug, it is safe to say that it does not cause epilepsy. It is also noteworthy that individuals with congenital 5α-reductase deficiency, caused by a mutation in the 5α-reductase type 2 gene (a condition with ambiguous genitalia), do not exhibit epilepsy. Although neurosteroid deficiency does not induce epilepsy, there is evidence that neurosteroids can modulate epileptogenesis (5) .
While finasteride does not provoke seizures in the general population, there are no prospective studies to determine whether inhibition of 5α-reductase by finasteride influences seizure susceptibility in individuals with epilepsy. There is a single anecdotal report of a woman with epilepsy taking finasteride for male pattern baldness who experienced an increase in seizure frequency and severity in association with finasteride use (6) . The doses of finasteride used clinically are in the range of 1 to 5 mg per day, which is far less than the doses of 30 to 100 mg/kg used in rats in the study by Lawrence et al. Furthermore, in humans, finasteride is selective for the type 2 5α-reductase isoform and less active on the type 1 enzyme that is the isoform predominantly present in the brain. This selectivity is not observed with the rat enzymes. In sum, finasteride, as administered clinically in humans, probably does not block neurosteroidogenesis sufficiently to influence seizure susceptibility under most circumstances.
When neurosteroid levels fluctuate, loss of seizure control can occur. A key clinical situation in which neurosteroids are a factor in seizure control is perimenstrual catamenial epilepsy. Rodents have a 4 to 5 day estrous cycle and studies of fluctuations in seizure susceptibility in cycling female rodents have not led to results that are relevant to the human menstrual cycle. In order to study the neurobiological basis of catamenial epilepsy and develop treatment approaches, a rat model was developed both to simulate the prolonged exposure to high levels of estrogen and progesterone that occur in the luteal phase of the 28-day human menstrual cycle as well as to replicate the withdrawal of allopregnanolone that occurs in conjunction with the fall in progesterone levels at the time of menstruation (7) . Prolonged elevated sex hormone levels are induced by gonadotrophin treatment, and 11 days later allopregnanolone is withdrawn by treatment with finasteride. Lawrence et al. utilized the catamenial epilepsy model in epileptic rats. They found an even greater exacerbation of seizures than ordinarily occurs in epileptic animals. This finding suggests that prolonged exposure to neurosteroids (and perhaps other hormonal changes in the catamenial epilepsy model) leads to heightened excitability in the epileptic brain that is revealed when the neurosteroids are withdrawn. A key alteration that has been associated with chronic neurosteroid exposure and could be a contributing factor is down-regulation of δ-subunit containing nonsynaptic GABA A receptors (8) .
Lawrence et al. conducted a final experiment in ovariectomized epileptic animals that had low serum progesterone levels maintained by subcutaneous implantation of a progesterone pellet. Unexpectedly, these animals also exhibited a huge (25-fold) increase in seizure frequency following finasteride treatment. Unfortunately, the authors did not study animals in which peripheral progesterone was completely eliminated. Nevertheless, the results of this last experiment suggest that the exacerbation of seizures that occurs following finasteride treatment is due to the inhibition of brain neurosteroid synthesis and is not caused by suppression of the conversion of peripheral (ovarian) progesterone to allopregnanolone. This important conclusion focuses attention squarely on brain neurosteroids as critical regulators of seizures in epilepsy. Clearly, more needs to be learned about the role of locally synthesized neurosteroids in epileptic brain circuits.
The paper by Lawrence et al. also has important implications for therapy. The authors demonstrate that allopregnanolone treatment rapidly terminates the finasteride-induced exacerbation of seizures, providing additional evidence that the increase in seizure frequency is because of a finasteride-induced reduction in neurosteroids and not some other action of the drug. More importantly, it supports the concept that neurosteroid replacement may be useful in the treatment of seizures associated with neurosteroid fluctuations, such as catamenial epilepsy (7) . In catamenial epilepsy, breakthrough seizures occur despite treatment with antiepileptic drugs. Previous studies (reviewed in 7) and the new results from Lawrence et al. support the potential of neurosteroids as a novel treatment approach for these pharmacoresistant seizures. (4):413-419. Brain inflammation is a major factor in epilepsy, but the impact of specific inflammatory mediators on neuronal excitability is incompletely understood. Using models of acute and chronic seizures in C57BL/6 mice, we discovered a proconvulsant pathway involving high-mobility group box-1 (HMGB1) release from neurons and glia and its interaction with Toll-like receptor 4 (TLR4), a key receptor of innate immunity. Antagonists of HMGB1 and TLR4 retard seizure precipitation and decrease acute and chronic seizure recurrence. TLR4-defective C3H/HeJ mice are resistant to kainateinduced seizures. The proconvulsant effects of HMGB1, like those of interleukin-1β (IL-1β), are partly mediated by ifenprodil-sensitive N-methyl-D-aspartate (NMDA) receptors. Increased expression of HMGB1 and TLR4 in human epileptogenic tissue, like that observed in the mouse model of chronic seizures, suggests a role for the HMGB1-TLR4 axis in human epilepsy. Thus, HMGB1-TLR4 signaling may contribute to generating and perpetuating seizures in humans and might be targeted to attain anticonvulsant effects in epilepsies that are currently resistant to drugs.

I
nflammation plays a prominent role in the etiology of symptomatic epilepsies that result from brain injuries, including those from stroke and status epilepticus. An emerging literature suggests inflammation and immune processes contribute to both drug-resistant temporal lobe epilepsy and epilepsies associated with cortical malformations. The expression of inflammatory mediators from glia and neurons in epileptic tissue indicates that the contribution to the pathology may be essential to the ictogenic or epileptogenic process, rather than merely epiphenomena. Insight into the key role of cytokines in epilepsies, especially that of interleukin-1β (IL-1β), has occurred via novel molecular and pharmacological studies, using in vivo models and genetically engineered mice with altered cytokine signaling (1) .
The chronic upregulation of IL-1β expression during epileptogenesis in activated astrocytes suggests a predominant role for astrocytes in sustaining activation of inflammatory cascades before the appearance of spontaneous seizures (1). IL-1β triggers a signaling pathway involving the IL-1 receptor 1, IL-1 receptor accessory protein complex, and myeloid differentiation primary response protein (MyD88) complex. The activation of the adaptor protein MyD88 by IL-1β simulates the Src family kinases, leading to NMDA receptor-2B phosphorylation and subsequent enhancement of NMDA-dependent Ca +2 influx. The NMDA-dependent Ca +2 influx then facilitates ictogenesis (2). IL-1β signaling and this intracellular cascade may alter the excitability of a neural network without cell loss, per se. In a study by Dubé and colleagues, hippocampal IL-1β levels are elevated chronically in activated astrocytes in rats with spontaneous seizures after febrile status epilepticus at postnatal day 11 (3) . The hippocampal IL-1β levels and spontaneous seizures were not dependent on cell loss, T2 MRI abnormalities in the hippocampus, or interictal EEG activity. Experimental febrile seizure duration in these rats influenced both the probability of developing limbic epilepsy and the severity and duration of the spontaneous seizures. However, the relationship between hippocampal IL-1β levels and the duration of initial neural activity (i.e., the duration of febrile status epilepticus) remains to be defined.
The pathways activated by IL-1β depend on the intracellular protein MyD88, which is central to signaling of other cell surface receptors, notably the Toll-like receptor 4 (TLR4) during pathogen recognition. However, in the absence of pathogen recognition, TLR-signaling pathways recognize molecules released from injured tissue, named damage-associated molecular patterns/proteins (DAMPs). High-mobility group box-1 (HMGB1) is a DAMP component of chromatin that is passively released from necrotic cells and actively secreted by cells in profound distress. In the Maroso et al. study, presented here, bicuculline and kainic acid models of epileptogenesis were used to understand the nature of HMGB1-TLR4 interactions, its intracellular signaling, and the role of HMGB1-TLR4 signaling in ictogenesis and seizure recurrence.
Using rats and human autopsy tissue, Maroso and colleagues observed increased TLR4 and HMGB1 expression in neurons, astrocytes, and microglia in the rat hippocampus (after intrahippocampal injections of kainic acid or bicuculline) as well as in human hippocampus from intractable temporal lobe epilepsy patients. The addition of recombinant HMGB1 to hippocampi treated with kainic acid had a proconvulsant effect, which was abolished in mice defective in TLR4 signaling. These data suggest that HMGB1-TLR4 signaling is intimately involved in seizure generation (i.e., ictogenesis). However, both the origin of HMGB1 release and the triggers for HMGB1 or TLR4 expression in glia or neurons during seizures in these models are far from clear. Maroso et al. demonstrated that 250 μM of glutamate in mixed neuronal/glia cultures caused excitotoxic cell death and subsequent release of HMGB1 protein into the extracellular medium. The authors could not detect HMGB1 synthesis or release from cultures of rat microglia or astrocytes after incubation with kainic acid, glutamate, or inflammatory mediators, such as tumor necrosis factor-α, ATP, IL-1β, or any combination of these three factors. However, ictal activity itself, hypoxia, and interactions with neurons may determine the rate of synthesis and release of HMGB1 from rat glial populations. In fact, HMGB1-TLR4 antagonists reduced the number of seizures, seizure duration, and increased latency to seizure onset in the bicuculline-induced nonlesional model of seizures. Thus, these data suggest that ictal activity in neurons is sufficient to facilitate HMGB1 synthesis and then subsequent release outside the cell.
One of the most compelling yet puzzling aspects of this study is the extent to which the HMGB1-TLR4 signaling pathway influences chronic epilepsy. Maroso et al. demonstrated that HMGB1 and TLR4 receptor antagonists were effective in blocking both acute seizures triggered by kainic acid and bicuculline, and in reducing seizure recurrence in chronic epileptic C57BL/6 mice. The downstream signaling events, denoted by presumed activation of Src protein kinases, phosphorylation of NR2B, and increased NMDA-mediated Ca +2 influx, can be blocked by ifenprodil, a sensitive blocker of NR2B-containing NMDA receptors. Ifenprodil blocks the proconvulsant effects of HMGB1 in the kainic acid model of acute seizures and decreases seizure recurrence in chronically epileptic C57BL/6 mice. However, ifenprodil fails to block acute seizures from kainic acid in the absence of the proconvulsant HMGB1 protein, suggesting inflammatory processes are necessary for the antiseizure effect of ifenprodil. An alternative hypothesis here might be that IL-1β signaling mediates some or all of the HMGB1 effects on ictogenesis and seizure recurrence. To evaluate the role of IL-1β in the HMGB1-TLR4 signaling, the most straightforward approach is to compare intraperitoneal injection to intrahippocampal injections of kainic acid in C57BL/6, mice, as the first model (i.e., with intraperitoneal injections) does not result in spontaneous seizures (4) . The data in Maroso et al. do not provide evidence for continuous HMGB1 synthesis and activity, nor does it distinguish the role of IL-1β pathway in these processes. However, given the proposed role of proinflammatory cytokines in astroctye synapses and neurodevelopmental disorders accompanied by epilepsy, including Fragile X and autism, developmental programmed cell death or neural activity-induced cell stress from any process may stimulate the HMGB1-TLR4 axis, promoting aberrant synaptic connectivity, neuronal excitability, and epileptogenesis (5-7).
Changes in glial and neuronal networks, cell death, and hyperexcitability all contribute to epileptogenesis. The contribution of HMGB1-TLR4 signaling to epileptogenesis or ictogenesis remains to be solved. HMGB1-TLR4 signaling may use only parts of the IL-1β pathways and thus, be a completely separate pathophysiology. Alternatively, HMGB1 may completely control the IL-1β pathway through modifications of intracellular signaling components or primary regulation of IL-1β, itself. The lack of cell death as a requirement and the presence of common signaling molecules for the proepileptogenic actions of IL-1β and HMGB1 suggest that pharmacologic interventions along this pathway may prove effective for current drug-resistant epilepsies, especially intractable pediatric epilepsies.
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